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Not getting older, getting better: the concept of 
successful aging
I wasted time, and now doth time waste me.
William Shakespeare, Richard ii (1595). Act V, scene 5. 
Successful aging is a relatively recent scientific term that 
may sound jarringly unusual or controversial, as aging has 
always been described as anything but ‘successful’. According 
to erickson’s personality theory (26), later adulthood and 
subsequent old age is the time of the ‘integrity vs. despair’ 
crisis, when the final developmental task of retrospection and 
assessment of one’s lifelong achievements and/or failures takes 
place, as well as dealing with loss and general preparation for 
death. if we look carefully at the age structure of any modern 
society though, we would not find many healthy elderly adults 
that are content just with peaceful contemplation of their past 
lives. A significant proportion of people aged 65 years or more 
remain healthy, active physically and mentally and contribute 
to their families, their jobs and the society in a unique way. 
improved healthcare, higher general level of education, the 
opportunity for lifelong learning and the increased ages 
of marriage and childbirth have contributed greatly to this 
tendency and have eventually made it global. 
the average lifespan of humans has only extended 
beyond middle-to-late adulthood in the last 100-150 years, 
largely because of the successes of the modern medicine in 
the prevention and treatment of infectious disease and the 
development of anti-inflammatory therapy. Successful aging, 
however, has been recognized, respected, and, often, revered, 
throughout human history. After all, Michelangelo finished his 
larger-than-life Pietà del Duomo at the age of 80 and would 
have probably finished his Pietà Rondanini, had he not made 
that unfortunate horseback promenade in the rain after a day’s 
hard work at the age of 88 (64). lorenzo da Ponte, the famous 
opera librettist and poet, who wrote for over 10 composers, 
produced the first New York public performance of Mozart’s 
Don Giovanni in 1826, at the age of 77 (over three decades 
after Mozart died – at the age of 35) and published his ‘Versi 
composti’ at the age of 83 (36). James Watson, one member 
of the famous duo that gave us the double helix model of the 
structure of DnA, published his Avoid Boring People: Lessons 
from a Life in Science in 2007, at the age of 79. the list of 
people who created truly spectacular works in their advanced 
age can thus go on for a long time. 
the formal concept of successful aging is not exactly 
new either. The standard definition is quite straightforward 
and is usually defined in terms of an individual retaining the 
ability to function independently in advanced age (71, 72, 84). 
More specifically, it has been described as ‘multidimensional 
process encompassing the avoidance of disease and disability, 
the maintenance of high physical and cognitive function, and 
sustained engagement in social and productive activities’ 
(65, 73). Understandably, the individual parameters of this 
description would be differently prioritized and differentially 
achieved in different people and the need for assistance would 
increase with progressing age. in any case, however, old age 
is not necessarily the time for regret and disability; it could be 
productive and gratifying to the aging persons, their families 
and the human society as a whole. 
All the progress in modern medicine and all the ‘healthy 
living’ obsession notwithstanding, however, successful aging is 
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still reserved to chosen few. Among these the careful observer 
could spot apparently ‘unhealthy’ lifelong habits and general 
happy-go-lucky approach to personal health at a rate practically 
indistinguishable from the rate in the general population. the 
search for the basis of this apparent discrepancy between 
conscious attempts to live ‘healthy’ and actual longevity and 
general health in old age has only begun. it is believed that 
at least part of the reason why not all healthy young people 
become eventually healthy old people is the phenomenon of 
antagonistic pleiotropy.
Antagonistic pleiotropy: where has all this 
natural selection brought us?
Too much of the good thing can be taxing. 
Mae West (1893-1980)
Natural selection results in survival of the fittest. This has 
been taught for decades now, and is essentially true (or as 
true as a generalization could be). The flaw in that concept, 
unfortunately, is demonstrated daily by the mundane fact that 
it is rarely the case that the fittest, healthiest, most vigorous 
young individuals age more successfully and live longer 
than their less fit counterparts. Barring potential confounding 
variables such as the incidence of work and vehicle incidents 
(which tend to be more common in youths than in adults, 
peaking again after age 65-70 (33, 67)), statistics shows that 
annual mortality peaks between the age of 35 and 45 for both 
sexes, decreasing smoothly until age 85-90 and peaking again 
for females while remaining at a plateau for males (20, 45, 69). 
it could be hypothesized that some genetic traits that provide 
advantages at young age may become disadvantageous in 
mature and old age. thus, a tradeoff could be proposed 
between the ability to survive to maturity and reproduce and 
the ability to survive long after the reproductive plans have 
been completed. Differential impact of individual genetic 
background in different ages could explain the fact that a 
certain percentage of the average healthy individuals, who 
thrive in childhood, develop successfully and produce healthy 
offspring, actually die before reaching middle adulthood while 
at the same time certain individuals do reach very old age. 
the idea of the tradeoff of genetic traits at different life 
stages (antagonistic pleiotropy) has been first expressed 
back in 1957 in an attempt to explain the phenomenon of 
aging (90). Presumably, longevity and successful aging are 
dependent on a set of pleiotropic genes. certain alleles of 
these genes ensure and promote fitness in young individuals, 
causing them to be selected and retained in the gene pool via 
reproduction. Same gene variants, however, result in poorer 
overall health and limited longevity in adults. Williams 
exhibited a remarkable insight, considering that in the 50s 
of the XX century the foundations of modern genetics have 
hardly been laid. he proposed that the selection pressure over 
a gene that in its different allelic forms confers an advantage 
at one age and a disadvantage at another is dependent both on 
the magnitudes of the effects themselves and on the timing of 
the effects, that is, an advantage provided during the period 
when successful reproduction is most probable would increase 
the total probability of positive selection for the respective 
gene variants (by passing them to the offspring) more than a 
proportionately similar disadvantage later on would decrease 
it. it makes perfect sense even in modern terms, as the allele 
pool diversity in the populations is maintained primarily by 
passing alleles on to the progeny (in cases when the carriers of 
these alleles are fit enough to reach maturity and reproduce). 
new alleles may also be introduced by de novo mutations, 
including the case when the alleles in question result in severe 
disability or early death precluding reproduction. 
in any case, however, any genetic advantage that causes 
delay in the loss of reproductive probability increases the 
positive selection for the associated pleiotropic genetic traits. 
For example, it is well known that the number of ovarian 
follicles in women decreases with age, reaching the critical 
number of about 1000 about the age of 51, which is the median 
age of onset of menopause (32). the loss of follicles actually 
starts early in life, but the rate of attrition is relatively stable 
throughout youth and early adulthood, until the average age of 
37-38, when the rate of follicle loss accelerates and the onset 
of menopause is triggered approximately a decade later (85). 
Factors that may slow down the rate of decline in reproductive 
probability (in this case, the rate of follicle attrition) intensifies 
positive selection, that is, women who can still ovulate at a 
later age have increased chances to pass their genes to the 
potential offspring. the overall result is that the peak of female 
fecundity and fertility is situated roughly between the ages 
of 20 and 30 and is common for most healthy females, but 
as age advances, the reproductive probability (i.e. fecundity) 
becomes more and more individually specific, with some 
women entering the menopause as early as 45 while others 
retain their menstrual cycle, may get pregnant and carry the 
pregnancy to term up to 50 years and beyond (though this is 
rare and the probability for it declines with every year after 
the fertility peak). Apart from cases where egg and embryo 
donation are used as means to resolve an infertility problem, 
fertility treatments in later adulthood require that the ovarian 
reserve is maintained beyond the age at which the accelerated 
follicle attrition starts, delaying reproductive senescence (that 
is, menopause). Without any intervention targeted at resolving 
the ovarian reserve issues, the major proportion of alleles 
in the gene pool would be due to births from mothers in the 
fertility peak. With the advent of iVF, however, the percentage 
of children born from previously infertile couples steadily 
increase every year, which means that at least a proportion of 
the genetic pool of today and in the future would be made of 
alleles which do not confer reproductive advantage; otherwise 
at least some of their carriers would have had a better chance 
to reproduce naturally. in summary, in a society with less-than-
developed medical care the process of antagonistic pleiotropy 
would select for individuals who exhibit high physical and 
reproductive fitness in their young age (working on premises 
of natural selection only), but in a society equipped with 
state-of-the-art medical arsenal, it would also work for 
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positive selection for individuals that retain their vigour and 
reproductive fitness longer than others. 
Another consequence of antagonistic pleiotropy would 
be that in the absence of medical care (e.g. wild animal 
populations, primitive human societies) post-reproductive 
periods be short and/or unusual. this is easily demonstrable. 
For example, unspayed females of domesticated animals 
such as dogs usually are capable of oestrus and sometimes of 
getting pregnant until very old age – that is, 10-12 or more 
years (sometimes until their death), though fertility eventually 
wanes away. For comparison, their counterparts living in the 
wild rarely live over 7-8 years, which means that at the time of 
their death they are still fully capable of reproduction. 
it has been proposed that the selection related to the 
likelihood to reproduce and the reproductive competitiveness 
has been driven towards individuals who are reasonably 
immunologically competent when young (that is, resistant 
to infectious disease), so that they could survive infant and 
adolescent stage and reach age when they can successfully 
produce progeny. increased immune reactivity in earlier age, 
however, seems to bring about unfavourable effects at a later 
age. For example, in european populations the prevalence of 
the so-called Ah8.1 or ‘super-B8’ hlA haplotype (A1-B8-
DR3) is quite high (5-20 %, depending on the population). 
Ah8.1 as a whole and the separate serotypes which constitute 
it have been found to be associated with increased risk for 
an impressive number of autoimmune diseases (diabetes 
type 1 – DR3, myasthenia gravis – B8, DR3; Graves disease 
and multiple endocrine autoimmunity – B8, DR3; systemic 
erythematous lupus – B8, DR3; celiac disease – B8, DR3) as 
well as increased risk for some types of cancer (8, 9, 29, 66). 
obviously, having any of these conditions at any age does 
not exactly contribute to successful aging, even with modern 
medical care. Ah8.1 is rarely seen indeed among the middle-
old and the oldest old (over 75 years) but nevertheless it is 
present at a rate of several per cent. its effect on longevity and 
successful aging seems to be modulated by other factors, among 
which are gender differences (women are more predisposed 
to autoimmune disease than men) and/or others (10, 11, 60). 
thus, the common european A1-B8-DR3 haplotype might 
be initially selected for its early positive effects, but as it is 
associated with a susceptibility to a variety of diseases in 
adulthood, the selective advantages it confers to the carrier 
actually diminish as young progresses into mature age. if, 
however, Ah8.1-associated immune dysfunctions had not 
developed until the beginning of old age, it is possible that its 
positive effects with regards to resistance to infections would 
continue, contributing to the successful aging process to the 
fewer Ah8.1-carriers who have eluded autoimmunity. 
the number of adult and elderly individuals increases 
constantly worldwide because of improved living conditions 
and the advances in medical care. this means that, sooner 
rather than later, the tradeoff between the advantages in old age 
conferred by alleles disadvantageous or neutral in young age 
would begin to show, providing the fascinating opportunity of 
studying the interplay between genetic factors and environment 
outside the framework of reproductive capacity and in the 
unique milieu of the aging cell. 
Differential role of DNA repair in aging 
The time to repair the roof is when the sun is shining.
John F. Kennedy (1917-1963)
Constant, systematical, efficient repair of DNA damage is 
considered to be the main mechanism of protection of living 
cells against potentially harmful modification of the blueprint 
of their major information carrier molecule. Accumulation of 
DnA damage is believed to play a major role in the processes 
of aging and, ultimately, death, as well as in triggering and 
promoting cancerous growth. At a glance, the optimal mode 
of action to delay or arrest cellular aging might seem pretty 
straightforward – making sure that the cells are maximally 
protected from the impact of DnA damaging agents. it turns 
out, however, that this will not be practical and is unlikely 
ever to work, for a variety of reasons. First, the amount of 
DnA damage that the cell needs to manage daily is generated 
under the influence of external factors as well as by internal 
physiological processes. For example, only the spontaneous 
occurrence of abasic sites accounts for some 5 × 103 - 104 
events per eukaryotic cell per day (25, 53) and this is only one 
very simple type of DnA damage that the cellular machinery 
knows how to recognize and repair. Second, it has been known 
for more than two decades that in some cells the repair of 
DnA is carried out preferentially on the actively transcribed 
genes only, selectively inhibiting the repair in nontranscribed 
chromatin (6, 34, 35). later, it has been proposed that in some 
terminally differentiated cells (i.e. cells which are unlikely 
to divide any more in their lifespan, such as mammalian 
neurons) this is not merely a consequence of the more 
dense, and, therefore, less accessible chromatin structure in 
the untranscribed DnA regions, but an active compromise 
between focusing the capacity of the cellular repair machinery 
on managing the DnA damage that is present at the moment in 
genes important for the function of the cell versus diverting a 
significant proportion of this capacity to checking and repairing 
damage that is not likely to have any consequences for the cell 
unless it ever needs to divide – which would be unusual for a 
terminally differentiated cell (15, 30, 58). Recently, it has been 
reported that some cells potentially capable of proliferation 
such as circulating quiescent human B-lymphocytes also 
maintain high efficiency of their transcription-dependent 
repair at the expense of suppression of global repair, thus 
becoming prone to accumulation of DnA damage in the case 
when DnA damage and call for proliferation coincide (38). 
obviously, very different mechanisms for making the decision 
when to repair and what to repair operate in undifferentiated 
and differentiated cells. 
not all individuals are equal in their ability to recognize 
and repair damage to their DnA in a timely fashion so as not 
to allow accumulation of unrepaired damage. The finding of 
the inter-individual variation in the capacity for DnA repair is 
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actually one of the ideas that assisted in the emergence of the 
concept of personalized healthcare in the last decades of the 
XX century as it effectively led to abandoning of the notion 
that a ‘clinically healthy’ individual is healthy indeed. it was 
much later, however, that it was discovered that temporal 
distribution of the manifestations of the same traits may 
determine whether they are good or bad for the individual who 
carries them at a discrete time point. in the aspect of DnA 
repair, this was verified only in the last 10 years, as it was 
originally believed that any variations in the genes coding for 
proteins participating in DnA repair would present as severe 
inborn disease. Such diseases are considered rare (the most 
common, xeroderma pigmentosum, has incidence of about 
1:250 000 – 1:500 000 live births) which is most probably 
related to the fact that many foetuses affected with inherited 
disease do not survive to term at all so they are not included in 
the statistics as genuine cases. it was only recently discovered 
that subtle polymorphic variants in some genes coding DnA 
repair proteins or chromatin-modifying molecules such as 
hMGA1 are quite common and fully compatible with life 
within and outside the womb, but may prove troublesome in 
later life. Such are, for example, the substitutions c8092A in 
ERCC1, Arg194trp and Arg399Gln in XRCC1 and lys751Gln 
in XPD. these polymorphisms seemingly do not have other 
significant effect on the health of the carrier apart from 
increasing the risk for development of cancer in middle and 
advanced age (40, 92). Some polymorphisms in the XPD gene 
(312Asn and, again, lys751Gln) may bring about an increase 
in the risk for senile cataract in carrier individuals, probably 
because of accelerated aging of the crystallins in the lens of 
the eye (81). Since risk of cancer generally increases with age, 
it is quite obvious that such polymorphic variants would fully 
exert their adverse effect late in life. their genetic carriership 
was probably not selected against in the process of human 
evolution (as we said before, the average lifespan of humans 
increased beyond late adulthood only in the last century or 
so), which makes these polymorphisms likely to be common 
in all populations. it is still unclear whether they convey any 
selective advantage in early life, but it seems that at least some 
DnA repair genes do play a role in individual development. 
Recently, P53, the ultimate tumour-suppressor gene, has also 
been reviewed in the light of the antagonistic pleiotropy theory, 
as it has been found that a combination of polymorphic variants 
of P53 and XRCC1 genotypes is associated with increased lung 
cancer risk in younger smokers but not in older smokers, while 
the wildtype allele combination increased lung cancer risk 
for individuals over the age of 60 (17). Similar studies have 
been conducted for association with certain P53 genotypes 
and fertility in humans (41). thus, wildtype p53 increases the 
opportunity to pass one’s genetic background to the progeny 
by increasing the odds of successful reproduction at young age 
as well as by protecting the organism against cancer, but exert 
their deleterious effects later in life by promoting aging, which 
includes increased occurrence of cancer in the elderly (17, 
41, 82). Methods for assessment of individual repair capacity 
are developing steadily (4, 12, 16, 22), therefore we could 
expect that opportunities for early detection of deficiencies 
in the capacity for DnA repair and intervention so as to 
prevent cancer and other adverse sequelae of accumulation of 
unrepaired DNA damage will become more efficient and more 
accessible in the near future. 
it has been known for some years that the expression of 
proteins participating in the maintenance of the chromatin 
structure such as the transcription regulator hMGA1 may be 
deregulated in cancer (13, 28, 74, 77). later, an unexpected 
relationship has been found between the levels of hMGA1 
and a condition typical of middle age such as insulin 
resistance. namely, a number of polymorphisms in the hmga1 
gene resulting in severe insulin resistance and pronounced 
hyperglycemia have been identified in animal models as 
well as in humans (18, 31). hyperglycemia usually produces 
an increased level of oxidative stress and associated DnA 
damage in mitochondria (5), and, since the accumulation of 
unrepaired damage in DnA is considered a basic carcinogenic 
mechanism, it has been proposed that inherently low levels of 
hMGA1 expression (e.g. resulting from carriership of gene 
polymorphisms) may actually lead to decreased efficiency of 
protection of the DnA of the cell against oxidative damage. As 
a result, potentially carcinogenic oxidative lesions gradually 
accumulate, setting the basis for subsequent malignant 
transformation (62). this is, however, once again, an event 
that may occur only after sufficient time has passed, allowing 
the damaging agents to hit their target repeatedly and the level 
of unrepaired damage to accumulate sufficiently as to trigger 
tumorigenesis – that is, when the individual is old enough. 
it could be hypothesized, however, that the insulin-resistant 
phenotype and some associated metabolic features (capacity 
for accumulating fat depots, ketogenic metabolism) might 
have actually presented a selective advantage to young carrier 
individuals in the historical times when food was often sparse 
and life expectancy was low, resulting in some degree of 
positive selection or at least in very low negative selection for 
this trait – at least, until relatively recent times (see below). 
Back in my day we didn’t have this: the 
emergence of aging-related diseases 
Middle age is when your age starts to show around your 
middle.
Bob hope (1903-2003)
the scale of impact of age-related disease for the individuals 
affected by it as well as for the healthcare system has only 
begun to show. it could be expected that this is actually just 
‘the tip of the iceberg’ and that the impact would continually 
increase in the next decades. As humans live longer, and their 
living conditions continue to improve, diseases and conditions 
related to aging that were seldom observed until not that long 
ago will readily emerge and develop on a global scale. it could 
be easily (and wrongly) assumed that all these ‘new’ diseases 
are a product of lifestyle and/or environmental factors and 
some of them indeed are (e.g. obesity). the grounds for these 
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erroneous assumptions could be best described as a post hoc 
fallacy. As age-related diseases, as their name shows, manifest 
relatively late in life, the short life expectancy of pre-modern 
people practically eliminated the affected individuals before 
their conditions could become apparent but oftentimes after 
they have passed their genes to the offspring. Also, many age-
related diseases and diseases that develop only a sufficient 
period of time after the initial encounter with the putative 
causative or triggering agent has passed are often preceded by 
other conditions which are now treatable or at least manageable. 
this means that while once the affected individuals often 
died because of the condition, nowadays, provided that the 
affected individual survives the initial attack, it is likely that 
the risk for the respective disease of aging to develop with 
time increases. examples are numerous. it is well known from 
clinical practice that myelodysplastic syndromes (MDS) often 
precede (sometimes by decades) the development of overt 
leukemia (59, 78). Myelodysplasias may produce potentially 
life-threatening incidents on their own (e.g. bleeding diathesis, 
reduced resistance to infectious disease) which before the 
advent of chemotherapy and the use of growth factors, such as 
erythropoietin and G-cSF, could be fatal, resulting in genuine 
reduction of the cases that would have potentially progressed 
to post-MDS leukemia. Post-streptococcal glomerulonephritis 
with subsequent renal failure and post-streptococcal rheumatic 
endocarditis are common late complications of infections with 
beta-hemolytic streptococci even today, but as recently as a 
century ago it was much more likely for the patient to die from 
the infection itself than from its late sequelae. Finally, diabetic 
ketoacidosis may be life-threatening even in modern settings; 
therefore, back in the times when etiological treatment was not 
available this condition was likely to kill the affected person 
before the late complications associated with prolonged 
hyperglycemia (e.g. metabolic syndrome) could develop. 
As of now, the role of antagonistic pleiotropy in human 
disease is studied intensively, as, apart from the obvious 
reason related to the differential patterns of aging of the 
global population; there are a number of human diseases and 
conditions which seem to be associated with carriership of 
certain alleles in different genes but have a significant, albeit 
difficult to evaluate association with environmental or chance 
factors as well. in other words, they are clearly heritable, 
according to data gathered by familial studies, but also seem to 
be dependent on other factors, therefore they have significant 
prevalence in all populations, and yet it is very hard to assess 
the risk for the disorder for the particular individual. Such 
are, for example, schizophrenia (about 1% in all populations), 
affective disorders (between 10 and 20% in all populations) and 
some autistic spectrum disorders (0.1% - 0.5% in populations 
where DSM-iV criteria are promptly followed, excluding 
Rett’s disorder as a proportion of the cases have been traced to 
be associated with a defect in a single gene) (1, 44). Recently 
it has been proposed that these and other conditions are related 
to receiving an inappropriately high dosage of alleles which, 
in lesser doses, confer some positive advantage (43). too 
high a gene dosage may be taxing and indeed, patients with 
schizophrenia or severe autism do have significant reduction 
in physical fitness coupled with reproductive disadvantage 
– for a variety of reasons. it is known that the lifespan in 
schizophrenia and bipolar disorder is often shorter than in the 
general population and that this is usually related to physical 
disease (metabolic syndrome, hyperlipidemia, cardiovascular 
disease, etc.) (24, 57). So far, however, the parameters of the 
proposed dosage effect and the elusive selective advantage of 
a smaller gene dosage have not been identified yet.
obesity is a major health problem on a global scale today 
and much research effort has been invested in unraveling 
the mechanisms that resulted in the impressive prevalence 
of obesity we see in modern societies. the ‘thrifty gene’ 
hypothesis proposes that allelic forms of certain genes have 
been selected for during evolution because of the singular 
advantage they confer to the carrier, namely, the capacity for fat 
storage (75, 87, 88). Apparently, lean metabolism has always 
been a luxury during human existence, as only individuals who 
had enough depots of fat stored when food was plentiful could 
survive periods of famine. Mild to moderate insulin resistance 
produces this ‘thrifty’ phenotype, as hyperglycemic states are 
associated with inhibition of lipolysis, causing accumulation of 
fat into lipid storage depots. When food is sparse, adipocytes 
of insulin resistant individuals hydrolyze readily the stored 
triglycerides, releasing fatty acids in the plasma to be used as 
fuel by the glucose-starved cells, allowing the individual to 
survive and pass their ‘thrifty’ genes on during famine while 
other, less ‘thrifty’ metabolizers, may die or at least their 
reproductive fitness would decline. Therefore, ability to use 
energy sparingly must have been an asset back in the times 
when reaching old age was a rare event, as insulin resistance 
usually develops insidiously and may precede overt diabetes 
type ii with years or even decades. nowadays, however, 
people have a very good chance of living beyond the age when 
prolonged hyperglycemia ultimately takes its toll, therefore 
the associated evolutionary advantage which has been selected 
for many centuries may eventually turn to a disadvantage in 
the modern man.
Eat right, exercise regularly, die anyway – do 
popular health fads and misconceptions have 
any scientific basis at all? 
 Let Time that makes you homely, make you sage,
The sphere of wisdom is the sphere of age. 
thomas Parnell, An elegy to an old Beauty (circa 1710), l. 
35.
there are numerous popular concepts related to behaviours or 
goals that are believed to be ‘healthy’ or to promote longevity. 
Here we would only deal with those which have a scientific 
basis, as all the others are a legion and some of them hardly 
deserve attention. 
the most commonly exploited ‘living healthy’ notions 
supported by research data are: maintaining low total 
cholesterol levels; prevention of hypercoagulable states (i.e. 
2708 Biotechnol. & Biotechnol. eq. 26/2012/1
the ‘an aspirin a day’ notion); abstaining from drinking alcohol; 
physical exercise, etc. extensive surveys among people who 
qualify for the ‘extreme longevity’ category (≥ 85 at the time 
of the interview), show, however, that the distribution of 
behaviour patterns (including habits related to personal health) 
among these oldest old does not differ significantly from that 
seen in the general population (68, 91). Moreover, it has been 
recently shown that hypercoagulability is actually compatible 
with successful aging and longevity (54, 83) and – surprisingly 
– that total cholesterol levels over 5 mmol/l in the age group 
over 70 years are positively associated with longevity owing 
to lower mortality from cancer and infection in the >5 mmol/l 
experimental subgroup (79, 89). this phenomenon could 
find its explanation in reverse antagonistic pleiotropy, that 
is, elevated cholesterol levels may contribute to morbidity 
and mortality in young age and adulthood via increasing the 
risk for development of vascular disease but, with age, via 
mechanism/s as of now unknown, this begins to be more of a 
selective advantage than a disadvantage. 
Somewhat similar is the situation with the control over 
body weight. it has been known for quite a long time that 
calorie deprivation of laboratory animals (about 60-70% of the 
amount of kilocalories the animal would have if fed ad libitum) 
extends their life and lowers the incidence of cancer and other 
age-related disease, possibly because of the decreased levels 
of oxidative stress (27, 49). it is, however, also known from 
clinical practice that people who are mildly overweight are 
more likely to survive and develop complications more rarely 
after acute events (e.g . incidences of atrial fibrillation) as well 
as in the course of a chronic disease (e.g. non-diabetic kidney 
failure) compared to their underweight and even normal 
weight counterparts (2, 48). it is only fair to note that in serious 
chronic disease it is more likely that patients in more advanced 
stage of the disease (and, therefore, more likely to develop 
complications) would be underweight, and that new-onset 
atrial fibrillation is more likely to develop in obese people 
(86). Still, such research results do raise interesting questions 
as to whether it is really good for anyone to try to conform to 
the Western ideal body image. 
 Many studies have elicited an inverse relationship between 
regular exercise and the risk of certain cancers (37). however, 
a differentiation ought to be made between physical activity 
that is physiologically compatible (with regards to gender, age, 
physical fitness, etc. of the individual) and inappropriate, often 
strenuous physical exercise. it has been repeatedly shown in 
animal models and in humans as well that intense physical 
exercise is accompanied by elevation of oxidative stress not 
only in the working muscles but in other tissues and organs as 
well (3, 55). oxidative stress is recognized as a major factor in 
carcinogenesis, therefore, it is possible that too much exercise 
may produce the exact opposite of the health advantages 
claimed to be associated with moderate exercise. 
Finally, it has been demonstrated that relative risks for 
coronary heart disease and stroke (conditions typically 
associated with aging) are actually reduced by moderate 
consumption of alcoholic beverages. in other words, the 
prevalence of cardiovascular disease and stroke has been 
found to be actually higher in non-drinkers than in moderate 
drinkers (51, 63). lately, it has been demonstrated that non-
binge drinking actually reduces the risk of cognitive decline 
and dementia in adult and old age (19, 56). While the line 
between alcohol use and alcohol abuse is very thin and it is 
therefore advisable not to drink at all, once again, this is a 
‘healthy living’ concept that requires careful evaluation. 
Could we really do anything in order to age 
successfully? 
Age is strictly a mind over matter. If you don’t mind, then it 
doesn’t matter. 
Mark twain (1835-1910)
Several properties associated with successful aging have 
been defined, among which two basic categories could be 
defined, namely, traits that are associated with actual physical 
health status and qualities related to personality and general 
attitude to life. Of the first category, the general characteristics 
considered to be related to increased chances for successful 
aging are less-than-usual for the age group health trouble (no 
diabetes, no cancer, no serious mental disease) and preserved 
cognitive and physical capacity (to an extent, depending on the 
actual age (e.g. ‘walks for exercise’ vs. ‘capable and/or willing 
to walk should the need arise’). the second type of properties 
is considered no less important than the first and comprises 
active engagement/satisfaction with life, general optimistic 
mindset towards life; and one’s spouse alive and (relatively) 
healthy (46, 70, 76). 
Another trait associated with longevity and successful 
aging seems to be appropriate physical activity, both leisure 
and non-leisure (possibly related to the fact that having a 
physically active job would compel the person to be more 
active than having a sedentary job). this seems to exert its 
beneficial effects on both components found to be associated 
with successful aging so far, i.e. the physical as well as the 
psychological status (23, 50, 52). 
All these traits positively associated with successful aging 
do have one common unifying feature – independence, both 
physical and psychological. it seems that the major prognostic 
factor for aging gracefully is sustained independence, which 
is only natural even in a purely physical aspect as people 
who suffer from serious diseases are much less likely to be 
independent. Both groups of traits characteristic of successful 
aging seem to be important and while neither could actually 
exist without the other; both could exert a synergistic effect 
towards living a long and full life. Modern medicine offers 
many opportunities to prevent or delay adverse health events 
(e.g. cancer screening, antidiabetic therapy, antihypertensive 
medication) and, with the advent of methodology for 
assessment of individual repair capacity, it could be 
expected that the process of making informed decisions so 
as to decrease the risk of late-age disease would be greatly 
facilitated in the near future. Moreover, several strategies 
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designed to ensure protection against one of the major pro-
aging and carcinogenic factors – the UV radiation – even after 
prolonged or repeated encounter with it, have been developed 
(7, 14, 21, 80). Also, the anticancer and anti-inflammatory 
properties of some substances commonly found in human food 
and beverages such as resveratrol and antocyanes in fresh fruit 
and vegetables, polyphenols in tea and coffee, compounds in 
herbs and spices such as curcumin, etc. have been thoroughly 
studied and confirmed (39, 42, 47, 61). The other major factor, 
however, the positive attitude and genuine interest in life are 
often solely dependent on the attitude of the person. therefore, 
living healthy is only one component of being healthy; living 
well is the other, without the latter the former does not seem to 
work as expected. 
Conclusions
To die healthy means to live well.
 Robert Green ingersoll (1833 – 1899) 
it has been proposed that centuries of human evolution have 
created a selection trend for traits that confer a selective 
advantage in the young while being disadvantageous in the 
elderly, termed antagonistic pleiotropy. the exploration of 
this area has just begun, as it was only in the last 100-150 
years that the lifespan of the average human began to extend 
beyond several years after reproductive age and ‘successful 
aging’ became more than a phenomenon. consequently, the 
scale and scope of the impact of age-related disease began 
to show and called for a new concept of the focus and the 
quality of the medical care in the modern society. As could 
be expected, in an effort to sustain active life in old age, along 
with the concepts supported with extensive research data, 
numerous health and longevity misconceptions also emerged. 
it could be only through careful research and assessment that 
the factors playing a role in the constitution of the phenotype 
of successful aging could be identified and only after that a 
strategy for increasing the chances for a long life including 
graceful aging could be devised. 
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